Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA – The Lancet June 26, 2023
Traces of psychedelics make you feel good, but so does placebo, finds unusual ‘self-blinding’ study | Science March 7, 2021March 5, 2021